Comparative outcome and prognostic factor analysis among MDS/AML patients with TP53 mutations, snps, and wild type
{{output}}
While variant TP53 is an adverse prognosis factor in myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML), current clinical prognosis and variation feature analysis of TP53 alterations remain limited. We evaluated 333 MDS/AML patients with TP53 mutatio... ...
